Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ACT-001 by Accendatech for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
ACT-001 is under clinical development by Accendatech and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...